Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials

Feldman, Steven R.; Gómez, Badhin; Meng, Xiangyi; Germino, Rebecca

doi:10.1080/09546634.2019.1708854

Cited by 6 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the onset speed of Adalimumab and In iximab remained slower than that of anti-IL17A [6].The anti-IL17A drugs prevalent in China are Scuchizumab and Iqizumab. Both drugs have similar e cacy in psoriatic lesion resolution and have a better rate of improvement in PASI than monoclonal antibodies [7][8][9]. Despite the presence of multiple psoriatic drugs, there is still potential for advancements, especially in terms of making the drugs affordable and in reducing double infection risk.…”

Section: Introductionmentioning

confidence: 99%

Screening and Identification of Potential Key Biomarkers in Psoriasis : Evidence From Bioinformatic Analysis

Yang

Xie

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Psoriasis is a chronic and prevalent skin condition brought on by various genetic and external factors. Till date, there is no cure for this disease. It is, therefore, crucial to examine the underlying mechanisms leading up to psoriasis. The goal of our study was to explore the mechanistic pathways involved in the molecular pathogenesis of psoriasis.Methods: Using Gene Expression Omnibus (GEO), we performed an extensive analysis of the transcript expression profile in psoriasis patients. The datasets GSE13355, GSE30999, and GSE106992, containing 239 pairs of normal and psoriatic skin samples were arbitrarily assigned to two non-overlapping cohorts for cross-validated differential gene expression analysis. The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment and gene set enrichment analysis (GSEA) were employed for interpretation, visualization, and unified recognition. The STRING database was used to construct the protein–protein interaction (PPI) network and the hub genes were established using Cytoscape. Additionally, both differentially regulated genes and functional likeness of hub genes were further examined in terms of gene activation and functional outcome. The correlation between normal tissue and infiltrating immune cells was analyzed by CIBERSORT. Moreover, ROC analysis was performed to distinguish between skin lesion samples and skin non-lesion samples. In addition, a signaling axis involving lnRNA, miRNA, mRNA, and ceRNA was generated with information from the DEmiRNA, DElncRNA, and DEmiRNA-DEmRNA relationship. Lastly, immunohistochemical evaluations were used to analyze the highest expression of single gene in the whole body within the Human Protein Atlas (HPA) database.Results: The genetic profiles of 239 pairs of normal and lesional skin samples were downloaded from three datasets in the GEO database. PPI network revealed a tight interaction among 197 differentially expressed genes (DEGs). Moreover, gene ontology analyses indicated that psoriasis-related DEGs mostly included viral defense genes, type I interferon axis, and its corresponding cellular responses. The Kyoto encyclopedia of genes and the DEGs enrichment analysis showed involvement of the NOD-like receptor signaling network, cytokine-cytokine receptor binding, and IL-17 signaling axis in psoriasis verses non-psoriatic tissues. GSEA analysis demonstrated that CXCL8 was only enriched in the "complement characteristic" pathway. ROC curves indicated that CXCL8 expression was highly effective in classifying both lesional and non-lesional skin samples (with AUC 0.941, 0,935, and 0.794 for GSE13355, GSE30999, and GSE 106992). Furthermore, CIBERSORT database indicated that CXCL8 was correlated to 22 types of infiltrating immune cells. In addition, 6 miRNAs were predicted to be related to CXCL8, including hsa-miR-1294, hsa-miR-140-3p, hsa-miR-185-5p, hsa-miR-4306, hsa-miR-4644, and hsa-miR-493-5p. Lastly, immunohistochemical analysis showed that CXCL8 was most widely distributed in lymphoid tissues.Conclusions: Based on our analysis, CXCL8 plays a key role in psoriatic development. Our comprehensive bioinformatics analysis of the GEO data provided new insights into the exploration of molecular mechanisms while searching for highly efficient therapeutic targets for treating psoriasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Screening and Identification of Potential Key Biomarkers in Psoriasis : Evidence From Bioinformatic Analysis

Yang

Xie

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review

Wang,

Sun,

Sun

2024

Journal of Affective Disorders

View full text Add to dashboard Cite

A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries

Vyas

Johns

Ali

et al. 2023

British Journal of Dermatology

View full text Add to dashboard Cite

Background Over 29 years of clinical application, the Dermatology Life Quality Index (DLQI) has remained the most used PRO in dermatology due to its robustness, simplicity and ease of use. Objectives This systematic review aimed to generate further evidence of its utility in randomised controlled trials and is the first to cover all diseases and interventions. Methods The methodology followed PRISMA guidelines and included seven bibliographic databases, searching articles published from January 1 1994 until November 16, 2021. Articles were reviewed independently by two assessors, and an adjudicator resolved any opinion differences. Results Of 3220 screened publications, 457 articles meeting eligibility criteria for inclusion, describing research on 198,587 patients, were analysed. DLQI scores were primary endpoints in 24 (5.3%) of studies. Most studies were of psoriasis (53.2%), although 68 different diseases were studied. Most study drugs were systemic (84.3%), with biologics 55.9% of all pharmacological interventions. Topical treatments comprised 17.1% of total pharmacological interventions. Non-pharmacological interventions were 13.8% of the total interventions, mainly laser therapy and UV treatment. 63.6% of studies were multicentre, with trials conducted in at least 42 different countries, and 41.7% were conducted in multiple countries. Minimal importance difference (MID) was reported in analysis of 15.1% of studies, but only 1.3% considered full score meaning banding of DLQI. 61 (13.4%) of studies investigated statistical correlation of DLQI with clinical severity assessment or other PRO/QoL tools. 62% to 86% of studies had within group scores differences greater than the MID in “active treatment arms”. The JADAD risk of bias scale showed that bias was generally low, as 91.4% of studies had JADAD scores of ≥3; only 0.44% of studies showed high risk from randomisation, 13.8% high risk from blinding and 10.4% high risk from unknown outcome of all participants in the studies. 18.3% of studies declared that they followed an intention-to treat (ITT) protocol, and imputation for missing DLQI data was used in 34.1% of studies. Conclusions This systematic review provides a wealth of evidence for use of the DLQI in clinical trials to inform researchers’ and clinicians’ decision for its further use. Recommendations are also made for improving the reporting of data from future RCT trials using DLQI.

show abstract

Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials

Cited by 6 publications

References 22 publications

Screening and Identification of Potential Key Biomarkers in Psoriasis : Evidence From Bioinformatic Analysis

Screening and Identification of Potential Key Biomarkers in Psoriasis : Evidence From Bioinformatic Analysis

Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review

A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries

Contact Info

Product

Resources

About